High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes

[1]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[2]  Chieh-Yu Liu,et al.  Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia , 2010, Haematologica.

[3]  Chieh-Yu Liu,et al.  Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. , 2009, Blood.

[4]  R. Demir,et al.  The distribution of angiopoietin-1, angiopoietin-2 and their receptors tie-1 and tie-2 in the very early human placenta. , 2008, Placenta.

[5]  N. Howlader,et al.  Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. , 2008, Blood.

[6]  M. Yao,et al.  Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. , 2008, Leukemia research.

[7]  M. Kitagawa,et al.  Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia , 2007, British journal of haematology.

[8]  K. Mądry,et al.  [Angiogenesis in bone marrow of myelodysplastic syndrome patients]. , 2007, Polskie Archiwum Medycyny Wewnetrznej.

[9]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[10]  Yung-Chi Hou,et al.  Expression and prognostic significance of angiopoietin in colorectal carcinoma , 2006, Journal of surgical oncology.

[11]  J. Palmblad,et al.  Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes. , 2006, Leukemia research.

[12]  C. Betsholtz,et al.  Endothelial/Pericyte Interactions , 2005, Circulation research.

[13]  G. Mufti.  Pathobiology, classification, and diagnosis of myelodysplastic syndrome. , 2004, Best practice & research. Clinical haematology.

[14]  C. Tait,et al.  Angiopoietins in tumours: the angiogenic switch , 2004, The Journal of pathology.

[15]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[16]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[17]  P. Sismondi,et al.  Angiopoietin‐2 expression in breast cancer correlates with lymph node invasion and short survival , 2003, International journal of cancer.

[18]  H. Chi,et al.  Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome , 2003, Leukemia.

[19]  H. Wada,et al.  Expression of angiopoietins and its clinical significance in non-small cell lung cancer. , 2002, Cancer research.

[20]  E. Estey,et al.  Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes , 2002, Cancer.

[21]  Richard A. Lang,et al.  Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  H. Kantarjian,et al.  Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome , 2002, British journal of haematology.

[23]  H. Zwierzina,et al.  Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. , 2002, Journal of hematotherapy & stem cell research.

[24]  P. Korkolopoulou,et al.  Prognostic evaluation of the microvascular network in myelodysplastic syndromes , 2001, Leukemia.

[25]  W. Kamps,et al.  Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor , 2001, British journal of haematology.

[26]  S. Kitano,et al.  Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. , 2001, Cancer research.

[27]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[28]  W. Berdel,et al.  Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. , 2000, Blood.

[29]  J. Kim,et al.  Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. , 2000, Circulation research.

[30]  E. Estey,et al.  Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. , 1999, Blood.

[31]  G. Pruneri,et al.  Angiogenesis in myelodysplastic syndromes , 1999, British Journal of Cancer.

[32]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[33]  K. Plate,et al.  Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. , 1998, The American journal of pathology.

[34]  Thomas N. Sato,et al.  Increased vascularization in mice overexpressing angiopoietin-1. , 1998, Science.

[35]  J. Loscalzo,et al.  Endothelial cells in physiology and in the pathophysiology of vascular disorders. , 1998, Blood.

[36]  H. Joensuu,et al.  High pre‐treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small‐cell lung cancer , 1998, International journal of cancer.

[37]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[38]  Y C Chen,et al.  Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. , 1995, Cancer genetics and cytogenetics.

[39]  L. Ellis,et al.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. , 1995, Cancer research.

[40]  A. Harris,et al.  Different angiogenic pathways characterize superficial and invasive bladder cancer. , 1995, Cancer research.

[41]  M. Toi,et al.  Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer , 1994, Japanese journal of cancer research : Gann.

[42]  A. Ullrich,et al.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.

[43]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[44]  J. Damilakis,et al.  Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. , 2005, Leukemia research.

[45]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  M. Shikami,et al.  Expression of endothelial cell-associated molecules in AML cells , 2002, Leukemia.

[47]  G. Rodgers,et al.  Evidence of increased angiogenesis in patients with acute myeloid leukemia. , 2000, Blood.

[48]  Z. Estrov,et al.  Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes , 2000 .